SCHEMBL2655502

SCHEMBL2655502

CCCN1Cc2nc3c(-c4ccc(C)nc4Cl)cccc3c(N)c2C1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ PARP1 P09874 1/20 0.35
▸ PARP2 Q9UGN5 1/20 0.35
▸ CRHR1 P34998 6/20 0.32
▸ GAA P10253 2/20 0.32
▸ ALDH1A1 P00352 3/20 0.32
▸ NPSR1 Q6W5P4 2/20 0.32
▸ MAPK10 P53779 1/20 0.32
▸ METAP2 P50579 1/20 0.31
▸ MAPK1 P28482 2/20 0.31
▸ MEN1 O00255 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ L3MBTL1 Q9Y468 1/20 0.30
▸ GABRG2 P18507 1/20 0.30
▸ GABRB3 P28472 1/20 0.30
▸ GABRA2 P47869 1/20 0.30
▸ PDE5A O76074 1/20 0.30
▸ HRH4 Q9H3N8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4921477 0.91 LMNA (0.36) HTTLMNAPARP1PARP2GAA
SCHEMBL4915502 0.90 LMNA (0.36) HTTLMNAPARP1PARP2GAA
SCHEMBL2661191 0.89 LMNA (0.35) HTTLMNAPARP1PARP2GAA
SCHEMBL2660720 0.87 GABRG2 (0.35) HTTLMNAPARP1PARP2CRHR1
SCHEMBL2660762 0.86 HTT (0.35) HTTLMNAPARP1PARP2CRHR1
SCHEMBL2660012 0.86 LMNA (0.38) HTTLMNAPARP1PARP2ALDH1A1
SCHEMBL2660780 0.85 GABRG2 (0.42) HTTLMNAPARP1PARP2GAA
SCHEMBL2660837 0.84 GABRG2 (0.34) HTTLMNAPARP1PARP2GAA
SCHEMBL2655382 0.84 LMNA (0.38) HTTLMNAPARP1PARP2GAA
SCHEMBL2660747 0.83 LMNA (0.35) HTTLMNAPARP1PARP2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF HTT 503/4885LMNA 1909/4885PARP1 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback